0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......


Basic View | Expanded View
 Showing 21-34 of 34 Articles

The field of multiple sclerosis (MS) has benefited immensely from brain magnetic resonance imaging (MRI) scans as a biomarker of white matter inflammatory lesions. Magnetic resonance imaging has become an essential component of clinical practice to confirm diagnosis, identify new therapies, stratify disease severity, and monitor treatment response. ...

Necrotizing autoimmune myopathy (NAM) is a recently defined subcategory of the acquired idiopathic myopathies, characterized clinically by the subacute onset of proximal weakness, elevated creatine kinase levels, and electromyography revealing an irritable myopathy.1 It is distinguished from other acquired inflammatory myopathies (eg, polymyositis and dermatomyositis) by the ...

Original Investigation 
Charles D. Kassardjian, MD; Vanda A. Lennon, MD, PhD; Nora B. Alfugham, MBBS; Michael Mahler, PhD; Margherita Milone, MD, PhD
Includes: Supplemental Content

Importance  Necrotizing autoimmune myopathy (NAM) is characterized pathologically by necrotic muscle fibers with absent or minimal inflammation. It is often accompanied by statin therapy, connective tissue diseases, cancer, and autoantibodies specific for signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl–coenzyme A reductase (HMGCR). Data are limited concerning differences among ...

Editorial: The Clinical Spectrum of Necrotizing Autoimmune Myopathy; Matthew N. Meriggioli, MD
Original Investigation 
Daniel M. Harrison, MD; Snehashis Roy, PhD; Jiwon Oh, MD; Izlem Izbudak, MD; Dzung Pham, PhD; Susan Courtney, PhD; Brian Caffo, PhD; Craig K. Jones, PhD; Peter van Zijl, PhD; Peter A. Calabresi, MD
Includes: Supplemental Content

Importance  Cortical lesions (CLs) contribute to physical and cognitive disability in multiple sclerosis (MS). Accurate methods for visualization of CLs are necessary for future clinical studies and therapeutic trials in MS.

Objective  To evaluate the clinical relevance of measures of CL burden derived from high-field magnetic ...

Editorial: Cortical Lesions in Multiple Sclerosis; Robert T. Naismith, MD
Editorial 
W. Oliver Tobin, MB BCh, PhD; Sean J. Pittock, MD

Neuromyelitis optica (NMO) spectrum disorders represent an evolving group of central nervous system–inflammatory autoimmune demyelinating diseases unified by a pathogenic autoantibody specific for the aquaporin 4 (AQP4) water channel.1 Disability is attack related and accrues incrementally, in contrast to multiple sclerosis, where disability generally occurs progressively in ...

Original Investigation 
Su-Hyun Kim, MD; In Hye Jeong, MD; Jae-Won Hyun, MD; AeRan Joung, RN; Hyo-Jin Jo, BS; Sang-Hyun Hwang, MD, PhD; Sooin Yun, MS; Jungnam Joo, PhD; Ho Jin Kim, MD, PhD
Includes: Supplemental Content

Importance  Despite the increased use of rituximab therapy in neuromyelitis optica spectrum disorder (NMOSD), the overall efficacy and safety of long-term rituximab treatment in a large group of patients is uncertain. Furthermore, the identification of a predictor of rituximab response is an important issue for assessing the ...

Editorial: Rituximab Therapy in Neuromyelitis Optica; W. Oliver Tobin, MB BCh, PhD; Sean J. Pittock, MD
Original Investigation 
Nicholas M. Gregg, MD; Albert E. Kim, MD; M. Edip Gurol, MD, MS; Oscar L. Lopez, MD; Howard J. Aizenstein, MD, PhD; Julie C. Price, PhD; Chester A. Mathis, PhD; Jeffrey A. James, BS; Beth E. Snitz, PhD; Ann D. Cohen, PhD; M. Ilyas Kamboh, PhD; Davneet Minhas, BS; Lisa A. Weissfeld, PhD; Erica L. Tamburo, MS; William E. Klunk, MD, PhD
Includes: Supplemental Content

Importance  Cerebral microbleeds (CMBs) are collections of blood breakdown products that are a common incidental finding in magnetic resonance imaging of elderly individuals. Cerebral microbleeds are associated with cognitive deficits, but the mechanism is unclear. Studies show that individuals with CMBs related to symptomatic cerebral amyloid angiopathy ...

Review 
Thijs van der Vaart, MSc; Iris E. Overwater, MSc; Rianne Oostenbrink, MD, PhD; Henriëtte A. Moll, MD, PhD; Ype Elgersma, PhD
Includes: Supplemental Content

Importance  Knowing the underlying etiology of intellectual disability in genetic disorders holds great promise for developing targeted treatments. Although successful preclinical studies and many positive clinical studies have been reported, it is unclear how many purported therapies have become established treatments. The quality of the clinical trials ...

Images in Neurology 
Sanjay Pandey, DM; Neelav Sarma, MD

This Images in Neurology article summarizes clinical features, diagnosis, and management of post-stroke stereotypy.

Viewpoint 
Jean-Baptiste LePichon, MD, PhD; Carol J. Saunders, PhD; Sarah E. Soden, MD

This Viewpoint reports on the development of next-generation sequencing and its transformative capacity in health care, which stems in part from the synergism between translational research and clinical programs.

Editorial 
Jacqueline A. French, MD; Kimford Meador, MD

Epilepsy is a common disease that affects 1 in 26 individuals in their lifetime.1 According to a National Institute of Neurological Disorders and Stroke assessment, with 2 million affected individuals, epilepsy ranks only fourth to migraine, stroke, and Alzheimer disease in the prevalence of neurological disorders. Epilepsy ...

Original Investigation 
Sarah C. MacDonald, BSc; Brian T. Bateman, MD, MSc; Thomas F. McElrath, MD, PhD; Sonia Hernández-Díaz, MD, DrPH
Includes: Supplemental Content

Importance  Between 0.3% and 0.5% of all pregnancies occur among women with epilepsy. Evidence suggests an increase in perinatal morbidity and mortality among women with epilepsy. However, these risks have not been quantified in large population-based samples.

Objective  To report on the risk for death and ...

Editorial: Risks of Epilepsy During Pregnancy; Jacqueline A. French, MD; Kimford Meador, MD
Original Investigation 
Courtney L. Sutphen, BS; Mateusz S. Jasielec, MS; Aarti R. Shah, MS; Elizabeth M. Macy, BA; Chengjie Xiong, PhD; Andrei G. Vlassenko, MD, PhD; Tammie L. S. Benzinger, MD, PhD; Erik E. J. Stoops, Eng; Hugo M. J. Vanderstichele, PhD; Britta Brix, PhD; Heather D. Darby, MSc; Manu L. J. Vandijck, MSc; Jack H. Ladenson, PhD; John C. Morris, MD; David M. Holtzman, MD; Anne M. Fagan, PhD
Includes: Supplemental Content

Importance  Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being targeted for AD secondary prevention trials. How early during the normal life span underlying AD pathologies begin to develop, their patterns of change over time, and their relationship with future cognitive decline remain to ...

Images in Neurology 
Kimmo J. Hatanpaa, MD, PhD; Franklin Fuda, DO; Prasad Koduru, PhD; Ken Young, MD; Bradley Lega, MD; Weina Chen, MD, PhD

An immunocompetent woman in her mid-60s initially presented with episodes of spasms and tremors in her right hand and forearm. Lymphoma cells were present in cerebrospinal fluid but not in bone marrow. Findings are diagnostic of the lymphomatosis cerebri variant of diffuse, large B-cell lymphoma.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts